Early-Stop for liver cancer drug combo trial
NCT ID NCT06320080
Summary
This early-stage study tested a new two-drug combination (TQB2223 and penpulimab) for people with advanced liver cancer that had spread. The main goal was to check the safety and initial signs of effectiveness of this treatment. The study was terminated after enrolling 22 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
-
Hubei Provincial Tumor Hospital
Wuhan, Hubei, 430079, China
-
Hunan Provincial Tumor Hospital
Changsha, Hunan, 410031, China
Conditions
Explore the condition pages connected to this study.